The Impacts of Rescheduling Cannabis

Rescheduling cannabis to Schedule III aims to balance medical use with controlling abuse potential. Ultimately, moving cannabis to Schedule III has the potential to drastically transform the operational, financial, and legal framework for all players in the cannabis sector, paving the way for extensive research, broader access, and greater acceptance.

Compliance

Registration

Entities need to register with state medical marijuana programs and the DEA for legal handling of these substances.

Inventory Management

Keep precise records of inventory receipts, distribution, and disposal.

Continue Reading…

Comprehensive Manufacturing Plan

Must demonstrate cGMP manufacturing.

Security Measures

Facilities require strong security, including alarms, surveillance, and secure storage, to deter theft and unauthorized access.

Reporting and Recordkeeping

Keep precise records of inventory receipts, distribution, and disposal.

Federal and State Regulations:

Adherence to both federal and, in some cases, more stringent state regulations is required.

Training and Education

Staff handling these substances should be trained in relevant laws and best practices.

Audits and Inspections

Facilities may undergo audits and inspections by state medical marijuana authorities and the DEA to ensure compliance.

Reporting Suspicious Activity

Any suspicious activities related to the diversion or misuse of these substances must be reported to the authorities.

Research & Development

Schedule I restrictions put extreme limits on growth opportunities, research and
 clinical studies for cannabis. Schedule III would open the door for funding & research.

Growth Opportunities

Regulatory barriers hinder cannabinoid research in the US, preventing therapeutic performance studies. Rescheduling cannabis to Schedule III would ease restrictions, enabling research and aligning state and federal laws, fostering studies on non-psychotropic cannabinoids like CBD.

Clinical Studies

Schedule I status restricts cannabis research. Rescheduling would facilitate study approvals and funding, encouraging the development of new medications. Recent legislative changes, such as HR-8454, support efficacy testing on cannabinoids. Kazmira is pursuing clinical studies to validate the effectiveness of products like Imperial Oil® and Silver Plume®.

Schedule 3 Therapeutics

Medical Applications Mentioned by HHS

Mentioned by HHS

The Department of Health and Human Services (HHS) regognizes the medical value of cannabis and mentioned specific application opportunities for cannabis in Schedule III.

Inflammatory
Conditions

Cannabis is being explored for treating inflammatory conditions like IBD.

Nausea and
Vomiting

Cannabis has been shown to help alleviate nausea and vomiting.

Pain
Management

Cannabis is often used for chronic pain relief, particularly where traditional medications are ineffective or cause unwanted side effects.

Neurological
Disorders

Cannabis may help treat neurological issues like epilepsy by reducing seizure frequency and severity.

Mental Health
Disorders

Studies continue on cannabis's impact on mental health, including anxiety and PTSD.

Appetite
Stimulation

Cannabis helps stimulate appetite in anorexic patients, countering weight loss.

Inflammatory
Conditions

Cannabis is being explored for treating inflammatory conditions like IBD.

Nausea and
Vomiting

Cannabis has been shown to help alleviate nausea and vomiting.

Neurological
Disorders

Cannabis may help treat neurological issues like epilepsy by reducing seizure frequency and severity.

Pain
Management

Cannabis is often used for chronic pain relief, particularly where traditional medications are ineffective or cause unwanted side effects.

Mental Health
Disorders

Studies continue on cannabis's impact on mental health, including anxiety and PTSD.

Appetite Stimulation

Cannabis helps stimulate appetite in anorexic patients, countering weight loss.